الفهرس Only 14 pages are availabe for public view
 |  | from | 305 |  |  |
| | | from | 305 | | |
Abstract
Lacidipine is a calcium channel blocker developed for oral administration. It is used in the treatment of hypertension and atherosclerosis. It also possesses an antioxidant effect. Lacidipine is a highly lipophilic drug of poor water solubility and undergoes extensive first-pass hepatic metabolism with a mean absolute bioavailability of about 10% (range 3-59%). It is completely metabolized in the liver by cytochrome P450 3A4 to pharmacologically inactive metabolites. This very low oral bioavailability restricts its use. So, lacidipine could be an excellent candidate for transdermal delivery. Transdermal drug delivery systems (TDDS) are one of the most rapidly advancing areas of novel drug delivery, which are designed to deliver a therapeutically effective amount of drug across a patient{u2019}s skin. Transdermal drug delivery systems offer many advantages over oral dosage forms including: avoiding hepatic metabolism, gastric degradation, minimizing systemic side effects due to site specific drug delivery, the easier administration and more patient compliance in addition to the possibility of immediate withdrawal of the treatment if necessary. However, only a few drugs could be delivered effectively through transdermal route due to the inability of most drugs to penetrate the barrier nature of stratum corneum.